Aureus Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Aureus Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-15,625	Closed	-$232K	–	189
2018 Q3	$232K	Hold	15,625	–	–	0.03%	174
2018 Q2	$263K	Hold	15,625	–	–	0.04%	162
2018 Q1	$358K	Hold	15,625	–	–	0.05%	128
2017 Q4	$404K	Buy	+15,625	New	+$315K	0.06%	128

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aureus Asset Management's CNCE Position: Q4 2018 in Review

Aureus Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2018, closing a stake of 15,625 shares — an estimated $232K sold.

Aureus Asset Management first reported a position in CNCE in Q4 2017 and held it in 4 quarters. The position peaked at $404K in Q4 2017. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2018.

Aureus Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Aureus Asset Management sold 15,625 Concert Pharmaceuticals, Inc. shares in Q4 2018, an estimated $232K.
Aureus Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Aureus Asset Management's Concert Pharmaceuticals, Inc. position peaked at $404K in Q4 2017.
93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2018.

Based on Aureus Asset Management's 13F filing for Q4 2018, filed 13 Feb 2019.